Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SN-011 is a potent small molecule inhibitor of the **Stimulator of Interferon Genes (STING)** pathway. It functions by targeting the STING protein, a central mediator of the innate immune response to cytosolic DNA, thereby preventing the downstream induction of Type I interferons (such as IFN-β) and pro-inflammatory cytokines. In the context of **age-related macular degeneration (AMD)**, SN-011 has been shown to mitigate immune-mediated retinal degeneration by blocking the polarized secretion of IFN-β and IL-17A, which are associated with photoreceptor apoptosis and choroidal disruption. By inhibiting the STING-driven pathogenic feed-forward loop, SN-011 helps preserve retinal architecture and function in preclinical models. It is primarily utilized as a pharmacological tool to investigate the therapeutic potential of STING inhibition in inflammatory and degenerative diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SN-011.